(Katzenelenbogen et al., 2020; Molgora et al., 2020; Binnewies et al., 2021) Furthermore, TREM2+ TAMs were described to co-express various factors that facilitate tumor immune evasion, such as Arg1, Gpnmb or Spp1. (Sharma et al., 2020; Lazaratos et al., 2022) Likewise, anti-inflammatory TREM2+ TAMs were reported in primary liver cancers of patients and in mouse models. The gene discussed is TREM2; the disease is liver cancer.